Abstract
Fusion between nonsynchronized cells leads to the formation of heterokarya which transiently activate Cyclin-dependent kinase 1 (Cdk1)/cyclin B1 and enter the prophase of the cell cycle, where they arrest due to a loss of Cdk1/cyclin B1 activity, activate p53, disorganize centrosomes, and undergo apoptosis. Here, we show that the down regulation of Cdk1/cyclin B is secondary to the activation of the DNA structure checkpoint kinase Chk2. Thus, syncytia generated by the fusion of asynchronous HeLa cells contain elevated levels of active Chk2 but not Chk1. Chk2 bearing the activating phosphorylation on threonine-68 accumulates in BRCA1 nuclear bodies when the cells arrest at the G2/M boundary. Inhibition of Chk2 by transfection of a dominant-negative Chk2 mutant or a chemical inhibitor, debromohymenialdesine, stabilizes centrosomes, maintains high cyclin B1 levels, and allows for a prolonged activation of Cdk1. Under these conditions, multinuclear HeLa syncytia do not arrest at the G2/M boundary and rather enter mitotis and subsequently die during the metaphase of the cell cycle. This mitotic catastrophe is associated with the activation of the pro-apoptotic caspase-3. Inhibition of caspases allows the cells to go beyond the metaphase arrest, indicating that apoptosis is responsible for cell death by mitotic catastrophe. In another, completely different model of mitotic catastrophe, namely 14.3.3σ-deficient HCT116 colon carcinoma cells treated with doxorubicin, Chk2 activation was also found to be deficient as compared to 14.3.3σ-sufficient controls. Inhibition of Chk2 again facilitated the induction of mitotic catastrophe in HCT116 wild-type cells. In conclusion, a conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe, provided that the checkpoint kinase Chk2 is inhibited. Inhibition of Chk2 thus can sensitize proliferating cells to chemotherapy-induced apoptosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- Casp-2a:
-
activated caspase-2
- Casp-3a:
-
activated caspase-3
- Cdk1:
-
cyclin dependent kinase-1
- Cyt. c:
-
cytochrome c
- DBH:
-
debromohymenialdisine
- DN:
-
dominant negative
- Env:
-
envelope glycoprotein complex
- GAPDH:
-
glyceraldehyde-3-phosphate dehydrogenase
- HIV:
-
human immunodeficiency virus
- KG:
-
karyogamy
- MMP:
-
mitochondrial membrane permeabilization
- mTOR:
-
mammalian target of rapamycin
- p53S15P:
-
p53 with phosphorylated serine 15
- RNAi:
-
RNA interference
- siRNA:
-
small interfering RNA
- SC:
-
single cell
- Syn:
-
syncytia
- Z-VAD.fmk:
-
N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
References
Barrios Sosa AC, Yakushijin K and Horne DA . (2000). J. Org. Chem., 65, 610–611.
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher kJ, Fraumeni JF, Birch JM, Li FP, Garber JE and Haber DA . (1999). Science, 286, 2528–2531.
Boya P, Andreau K, Poncet D, Zamzami N, Perfettini J-L, Metivier D, Ojcius DM, Jaattela M and Kroemer G . (2003). J. Exp. Med., 197, 1323–1334.
Castedo M, Ferri KF, Blanco J, Roumier T, Larochette N, Barretina J, Amendola A, Nardacci R, Metivier D, Este JA, Piacentini M and Kroemer G . (2001). J. Exp. Med., 194, 1097–1110.
Castedo M, Perfettini J-L, Roumier T and Kroemer G . (2002a). Cell Death Differ., 9, 1287–1293.
Castedo M, Perfettini J-L, Roumier T, Valent A, Raslova H, Yakushijin K, Horne DA, Feunteun J, Lenoir G, Vainchenker W and Kroemer G . (2004). Oncogene, in press.
Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, Andreau K, Perfettini J-L, Armendola A, Nardacci R, LeDuc P, Ingber DE, Este JA, Modjtahedi N, Piacentini M and Kroemer G . (2002b). EMBO J., 21, 4070–4080.
Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B . (1999). Nature, 401, 616–620.
Chehab NH, Malikzay A, Appel M and Halazonetis TD . (2000). Genes Dev., 14, 278–288.
Curman D, Cinel B, Williams DE, Rundle N, Block WD, Goodarzi AA, Hutchins JR, Clarke PR, Zhou BB, Lees-Miller SP, Andersen RJ and Roberge M . (2001). J. Biol. Chem., 276, 17914–17919.
Daugas E, Susin SA, Zamzami N, Ferri K, Irinopoulos T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J and Kroemer G . (2000). FASEB J., 14, 729–739.
Falck J, Maitland N, Syljuasen RG, Bartek J and Lukas J . (2000). Nature, 410, 842–847.
Ferri KF, Jacotot E, Blanco J, Esté JA, Zamzami A, Susin SA, Brothers G, Reed JC, Penninger JM and Kroemer G . (2000a). J. Exp. Med., 192, 1081–1092.
Ferri KF, Jacotot E, Geuskens M and Kroemer G . (2000b). Cell Death Differ., 7, 1137–1139.
Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM and Piwnica-Worms H . (2000). J. Biol. Chem., 275, 5600–5605.
Heald R, McLoughlin M and McKeon F . (1993). Cell, 74, 463–474.
Hirose Y, Berger MS and Pieper RO . (2001). Cancer Res., 61, 5843–5849.
Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G and Wang Y . (2001). J. Biol. Chem., 276, 17693–17698.
Jin P, Hardy S and Morgan DO . (1998). J. Cell. Biol., 141, 875–885.
Lee J-S, Collin KM, Brown AL, Lee C-H and Chung JH . (2000). Nature, 404, 201–204.
Lock RB and Stribinskiene L . (1996). Cancer Res., 56, 4006–4012.
Lou Z, Minter-Dykhouse K, Wu X and Chen J . (2003). Nature, 421, 957–961.
Lukas C, Falck J, Barkova J, Bartek J and Lukas J . (2003). Nat. Cell. Biol., 5, 255–260.
Mackey MA, Zhang XF, Hunt CR, Sullivan SJ, Blum J, Laszlo A and Roti Roti JL . (1996). Cancer Res., 56, 1770–1774.
Matsuoka S, Huang M and Elledge SJ . (1998). Science, 282, 893–1897.
McGowan CH . (2002). Bioessays, 24, 502–511.
Meijers-Heijboe H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N and Stratton MR . (2002). Nat. Genet., 31, 55–59.
Melo J and Toczyski D . (2002). Curr. Opin. Cell. Biol., 14, 237–245.
Nigg EA . (2001). Nat. Rev. Mol. Cell. Biol., 2, 21–32.
Peng C-Y, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H . (1997). Science, 277, 1501–1505.
Perfettini J-L, Roumier T, Castedo M, Larochette N, Boya P, Reynal B, Lazar V, Ciccosanti F, Nardacci R, Penninger JM, Piacentini M and Kroemer G . (2004). J. Exp. Med., in press.
Pines J and Hunter T . (1994). Embo J., 13, 3772–3781.
Roninson IB, Broude EV and Chang B-D . (2001). Drug Resistance Updates, 4, 303–313.
Roumier T, Castedo M, Perfettini J-L, Andreau K, Metivier D, Zamzami N and Kroemer G . (2003). Biochem. Pharmacol., 66, 1321–1329.
Senderowicz AM . (2003). Cancer Chemother. Pharmacol., 52, S61–S73.
Seo GJ, Kim SE, Lee YM, Lee JW, Lee JR, Hahn MJ and Kim ST . (2003). Biochem. Biophys. Res. Commun., 304, 339–343.
Sheih SY, Ahn J, Tamai K, Taya Y and Prives C . (2000). Genes. Dev., 14, 289–300.
Smits VA and Medema RH . (2001). Biochim. Biophys. Acta., 1519, 1–12.
Stevens C, Smith L and La Thangue NB . (2003). Nat. Cell. Biol., 5, 401–409.
Takada S, Kelkar A and Theurkauf WE . (2003). Cell, 113, 87–99.
Tsvetkov L, Xu X, Li J and Stern DF . (2003). J. Biol. Chem., 278, 8468–8475.
Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP and Nevanlinna H . (2002). Am. J. Hum. Genet., 71, 432–438.
van den Heuvel S and Harlow E . (1993). Science, 262, 2050–2054.
Xu J and Du W . (2003). FEBS Lett., 19, 209–212.
Yang S, Kuo C, Bisi JE and Kim MK . (2002). Nat. Cell. Biol., 4, 865–870.
Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW and Pommier Y . (2002). Cancer Res., 62, 5743–5748.
Acknowledgements
We thank Dr. Bernd Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD, USA) for cell lines, Dr. Thierry Soussi (Institut Curie, Paris, France) for cDNA constructs, Vladimir Lazar (Institut Gustave Roussy, Villejuif, France) for RT-PCR analyses; Didier Métivier, Nathanael Larochette (CNRS, Villejuif, France) for assistance, and the NIH AIDS reagents program (Bethesda, MD, USA) for cell lines. This work has been supported by a special Grant from LNC, as well as Grants from ANRS, FRM, European Commission (QLG1-CT-1999-00739 and Contract No. QLK3-CT-20002-01956) (to GK).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Castedo, M., Perfettini, JL., Roumier, T. et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23, 4353–4361 (2004). https://doi.org/10.1038/sj.onc.1207573
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207573
Keywords
This article is cited by
-
N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma
Scientific Reports (2022)
-
Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide
Medical Oncology (2022)
-
A link between mitotic defects and mitotic catastrophe: detection and cell fate
Biology Direct (2021)
-
VALD-3, a Schiff base ligand synthesized from o-vanillin derivatives, induces cell cycle arrest and apoptosis in breast cancer cells by inhibiting the Wnt/β-catenin pathway
Scientific Reports (2021)
-
Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment
Journal of Cancer Research and Clinical Oncology (2021)